Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight

New York, USA, June 10, 2026 (GLOBE NEWSWIRE) -- Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight

The lupus nephritis clinical trial analysis report delivers important insights into ongoing research of 35+ pipeline lupus nephritis drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

DelveInsight’s 'Lupus Nephritis Pipeline Insight 2026' report provides comprehensive global coverage of pipeline therapies for lupus nephritis across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the lupus nephritis domain.

Lupus Nephritis Clinical Trial Analysis Summary

• DelveInsight’s lupus nephritis pipeline report depicts a robust space with 30+ active players working to develop 35+ pipeline lupus nephritis drugs. 
• Key lupus nephritis companies, such as Novartis, Simcere Pharmaceutical Co., Ltd, Nanjing Immunophage Biotech Co., Ltd, Kyverna Therapeutics, Century Therapeutics, Adicet Bio, Resolve Therapeutics, Dragonfly Therapeutics, Kite, A Gilead Company, Regeneron Pharmaceuticals Inc., and others, are evaluating new lupus nephritis drugs to improve the treatment landscape.
• Promising pipeline lupus nephritis therapies, such as Lanalumab, SIM0278, IPG11406, KYV-101, CNTY-101, ADI-001, RSLV-145, DF5201, SIM 0721, KITE-363, VONSETAMIG, and others, are in different phases of lupus nephritis clinical trials.
• Approximately 12+ lupus nephritis drugs are in the late and mid stages of development.
• Notable MoAs in lupus nephritis clinical trials include BAFF-R inhibitor, Interleukin 2 replacements, EBI2 antagonist, Anti-CD19, CD19 CAR-NK kills B-cells, Anti-CD20, and others.

Request a sample and discover the recent advances in lupus nephritis drug development @ https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight

What is Lupus Nephritis?

Lupus nephritis is a serious complication of systemic lupus erythematosus, an autoimmune disorder in which the immune system mistakenly attacks the body’s own tissues. In lupus nephritis, this immune-mediated damage specifically targets the kidneys, leading to inflammation of the glomeruli, the tiny filtering units responsible for removing waste and excess fluids from the blood. Over time, this inflammation can impair kidney function, causing symptoms such as proteinuria, hematuria, swelling in the legs or face, and high blood pressure. If left untreated, lupus nephritis can progress to chronic kidney disease or even kidney failure, making early diagnosis and appropriate immunosuppressive treatment critical for preserving renal function and improving patient outcomes.

Find out more about lupus nephritis drug development @ Lupus Nephritis Treatment

A snapshot of the Pipeline Lupus Nephritis Drugs mentioned in the report:

Learn more about the emerging lupus nephritis therapies @ Lupus Nephritis Clinical Trials 

Stuti Mahajan, consulting manager at DelveInsight, said that the increasing prevalence of autoimmune diseases and growing adoption of targeted biologics and novel immunosuppressive therapies are key drivers accelerating growth in the Lupus Nephritis treatment market.

Recent Developments in Lupus Nephritis Treatment Space

• In February 2026, Fate Therapeutics provided an update that the company is advancing towards the commencement of its first planned Phase II clinical trial in lupus nephritis.
• In October 2025, Adicet Bio, Inc. announced initial safety and efficacy data from the first seven patients dosed with ADI-001 in the ongoing Phase I study evaluating ADI-001 as a potential treatment for patients with autoimmune diseases. 
• In June 2025, the REGENCY (NCT04221477) Phase III trial demonstrated that obinutuzumab paired with standard therapy had greater efficacy than standard therapy alone in treating lupus nephritis. Study results from Richard A. Furie, MD, and colleagues were published in the New England Journal of Medicine. 
• In May 2025, AbelZeta Pharma, Inc. announced that the U.S. Food and Drug Administration (FDA) had granted Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational therapy, C-CAR168, for the treatment of refractory Systemic Lupus Erythematosus (SLE), including Lupus Nephritis (LN).
• In April 2025, Fate Therapeutics announced that the U.S. Food and Drug Administration (FDA) had granted Regenerative Medicine Advanced Therapy (RMAT) designation for the lupus treatment candidate FT819. This designation signifies that a therapy meets specific requirements and is promising enough that the FDA wants to help move it through development faster. This is a cell therapy that Fate Therapeutics has been developing to treat active moderate to severe Systemic Lupus Erythematosus (SLE), including lupus nephritis (LN).

Scope of the Lupus Nephritis Pipeline Report 

• Coverage: Global 
• Lupus Nephritis Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Lupus Nephritis Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Lupus Nephritis Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
• Lupus Nephritis Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
• Lupus Nephritis Therapeutics Assessment By Mechanism of Action: BAFF-R inhibitor, Interleukin 2 replacements, EBI2 antagonist, Anti-CD19, CD19 CAR-NK kills B-cells, Anti-CD20, and others
• Key Lupus Nephritis Companies: Novartis, Simcere Pharmaceutical Co., Ltd, Nanjing Immunophage Biotech Co., Ltd, Kyverna Therapeutics, Century Therapeutics, Adicet Bio, Resolve Therapeutics, Dragonfly Therapeutics, Kite, A Gilead Company, Regeneron Pharmaceuticals Inc. and others.
• Key Lupus Nephritis Pipeline Therapies: Lanalumab, SIM0278, IPG11406, KYV-101, CNTY-101, ADI-001, RSLV-145, DF5201, SIM 0721, KITE-363, VONSETAMIG and others.

Dive deep into rich insights for new lupus nephritis treatments, visit @ Lupus Nephritis Drugs

Table of Contents

For further information on the lupus nephritis cure research, reach out @ Medication for Lupus Nephritis Treatment

Related Reports

Lupus Nephritis Market

Lupus Nephritis Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key lupus nephritis companies, including Roche, Novartis, Alexion Pharmaceuticals, AstraZeneca, Cabaletta Bio, AbelZeta, Aurinia Pharmaceuticals, Otsuka Pharmaceuticals, GlaxoSmithKline, and others.

Systemic Lupus Erythematosus Market

Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key SLE companies including Biogen, Novartis, MorphoSys, Idorsia Pharmaceuticals, Viatris, RemeGen, UCB Pharma, Genentech, Bristol Myers Squibb, AbbVie, and others.

Systemic Lupus Erythematosus Clinical Trial Analysis

Systemic Lupus Erythematosus Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key SLE companies, including Roche, Biogen, Viatris Inc., Novartis, Qilu Pharmaceutical, ImmuPharma, Beijing Mabworks Biotech Co., Ltd., Zenas Biopharma, AbbVie, Beijing InnoCare Pharma Tech Co., Ltd., Alumis Inc., Galapagos NV, Palleon Pharmaceuticals, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Johnson & Johnson, Merck KGaA, Resolve Therapeutics, ILTOO Pharma, Argenx, Cartesian Therapeutics, Keymed Biosciences Co., Ltd, BioSenic, Eisai, Vertex Pharmaceuticals, Kyverna Therapeutics, Miltenyi Biomedicine, Astrazeneca, Otsuka Pharmaceutical, Fresh Tracks Therapeutics, Nucleome Therapeutics, OMass Therapeutics, and others.

IgA Nephropathy Market 

IgA Nephropathy Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key IgAN companies including Novartis, F. Hoffmann-La Roche, Ionis Pharmaceuticals, AstraZeneca (Alexion Pharmaceuticals), Vertex Pharmaceuticals, Otsuka Pharmaceutical, Biogen, Arrowhead Pharmaceuticals, NovelMed, Q32 Bio, Walden Biosciences, Takeda Pharmaceutical, Vera Therapeutics, and others.

IgA Nephropathy Clinical Trial Analysis

IgA Nephropathy Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key IgAN companies, including Novartis Pharmaceuticals, Biohaven, Ltd., Keymed Biosciences Co., Ltd., Guangdong Hengrui Pharmaceutical Co., Ltd., ADARx Pharmaceuticals Inc., Biogen, Suzhou Rigerna Therapeutics, Wuxi BioCity Biopharmaceutics Co., Ltd., Transcenta Holding, Climb Bio, Chengdu Suncadia Medicine Co., Ltd., Purespring Therapeutics, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur 

info@delveinsight.com 

+14699457679